169 related articles for article (PubMed ID: 8329699)
1. Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis?
Hervio L; Chapman MJ; Thillet J; Loyau S; Anglés-Cano E
Blood; 1993 Jul; 82(2):392-7. PubMed ID: 8329699
[TBL] [Abstract][Full Text] [Related]
2. Effects of lipoprotein(a) on the binding of plasminogen to fibrin and its activation by fibrin-bound tissue-type plasminogen activator.
Anglés-Cano E; Hervio L; Rouy D; Fournier C; Chapman JM; Laplaud M; Koschinsky ML
Chem Phys Lipids; 1994 Jan; 67-68():369-80. PubMed ID: 8187237
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of fibrinolysis by lipoprotein(a).
Anglés-Cano E; de la Peña Díaz A; Loyau S
Ann N Y Acad Sci; 2001; 936():261-75. PubMed ID: 11460483
[TBL] [Abstract][Full Text] [Related]
4. Lp(a) particles mold fibrin-binding properties of apo(a) in size-dependent manner: a study with different-length recombinant apo(a), native Lp(a), and monoclonal antibody.
Kang C; Dominguez M; Loyau S; Miyata T; Durlach V; Anglés-Cano E
Arterioscler Thromb Vasc Biol; 2002 Jul; 22(7):1232-8. PubMed ID: 12117743
[TBL] [Abstract][Full Text] [Related]
5. Multiple binding with identical linkage: a mechanism that explains the effect of lipoprotein(a) on fibrinolysis.
Hervio L; Durlach V; Girard-Globa A; Anglés-Cano E
Biochemistry; 1995 Oct; 34(41):13353-8. PubMed ID: 7577920
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces.
Hancock MA; Boffa MB; Marcovina SM; Nesheim ME; Koschinsky ML
J Biol Chem; 2003 Jun; 278(26):23260-9. PubMed ID: 12697748
[TBL] [Abstract][Full Text] [Related]
7. The antifibrinolytic effect of lipoprotein(a) in heterozygous subjects is modulated by the relative concentration of each of the apolipoprotein(a) isoforms and their affinity for fibrin.
Hervio L; Girard-Globa A; Durlach V; Anglés-Cano E
Eur J Clin Invest; 1996 May; 26(5):411-7. PubMed ID: 8796369
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein Lp(a) and atherothrombotic disease.
de la Peña-Díaz A; Izaguirre-Avila R; Anglés-Cano E
Arch Med Res; 2000; 31(4):353-9. PubMed ID: 11068075
[TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of novel lysine-independent apolipoprotein(a)-binding sites in fibrin(ogen) alphaC-domains.
Tsurupa G; Ho-Tin-Noé B; Anglés-Cano E; Medved L
J Biol Chem; 2003 Sep; 278(39):37154-9. PubMed ID: 12853452
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the interaction of recombinant apolipoprotein(a) with modified fibrinogen surfaces and fibrin clots.
Sangrar W; Koschinsky ML
Biochem Cell Biol; 2000; 78(4):519-25. PubMed ID: 11012092
[TBL] [Abstract][Full Text] [Related]
11. Influence of lipoprotein (a) levels and isoforms on fibrinolytic activity--study in families with high lipoprotein (a) levels.
Falcó C; Estellés A; Dalmau J; España F; Aznar J
Thromb Haemost; 1998 Apr; 79(4):818-23. PubMed ID: 9580386
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen: a novel mechanism for lipoprotein(a)-mediated inhibition of plasminogen activation.
Feric NT; Boffa MB; Johnston SM; Koschinsky ML
J Thromb Haemost; 2008 Dec; 6(12):2113-20. PubMed ID: 18983515
[TBL] [Abstract][Full Text] [Related]
13. Antifibrinolytic effect of single apo(a) kringle domains: relationship to fibrinogen binding.
Rahman MN; Petrounevitch V; Jia Z; Koschinsky ML
Protein Eng; 2001 Jun; 14(6):427-38. PubMed ID: 11477223
[TBL] [Abstract][Full Text] [Related]
14. Effect of individual plasma lipoprotein(a) variations in vivo on its competition with plasminogen for fibrin and cell binding: An in vitro study using plasma from children with idiopathic nephrotic syndrome.
Soulat T; Loyau S; Baudouin V; Maisonneuve L; Hurtaud-Roux MF; Schlegel N; Loirat C; Anglés-Cano E
Arterioscler Thromb Vasc Biol; 2000 Feb; 20(2):575-84. PubMed ID: 10669658
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein(a) and plasminogen interactions with fibrin: a study with recombinant apolipoprotein(a) and isolated plasminogen fragments.
Rouy D; Koschinsky ML; Fleury V; Chapman J; Anglés-Cano E
Biochemistry; 1992 Jul; 31(27):6333-9. PubMed ID: 1627572
[TBL] [Abstract][Full Text] [Related]
16. Lipoprotein(a) isoforms display differences in affinity for plasminogen-like binding to human mononuclear cells.
Kang C; Durlach V; Soulat T; Fournier C; Anglés-Cano E
Arterioscler Thromb Vasc Biol; 1997 Oct; 17(10):2036-43. PubMed ID: 9351369
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the effects of Apo(a) kringle IV-10 and plasminogen kringles on the interactions of lipoprotein(a) with regulatory molecules.
Xue S; Green MA; LoGrasso PV; Boettcher BR; Madison EL; Curtiss LK; Miles LA
Thromb Haemost; 1999 Mar; 81(3):428-35. PubMed ID: 10102473
[TBL] [Abstract][Full Text] [Related]
18. The solution phase interaction between apolipoprotein(a) and plasminogen inhibits the binding of plasminogen to a plasmin-modified fibrinogen surface.
Sangrar W; Gabel BR; Boffa MB; Walker JB; Hancock MA; Marcovina SM; Horrevoets AJ; Nesheim ME; Koschinsky ML
Biochemistry; 1997 Aug; 36(34):10353-63. PubMed ID: 9265615
[TBL] [Abstract][Full Text] [Related]
19. Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. In vitro studies in a plasma milieu.
Rouy D; Grailhe P; Nigon F; Chapman J; Anglés-Cano E
Arterioscler Thromb; 1991; 11(3):629-38. PubMed ID: 1827591
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein(a), fibrin binding, and plasminogen activation.
Loscalzo J; Weinfeld M; Fless GM; Scanu AM
Arteriosclerosis; 1990; 10(2):240-5. PubMed ID: 2138452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
